Abstract
Cannabinoids, the active components of the cannabis plant, have merit as an anti-emetic and appetite stimulant in people with cancer. Recently, interest in cannabinoids has increased since reports that cannabinoids have anti-tumour activity. Although the mechanisms underlying these effects have yet to be fully elucidated, a broad spectrum of effects have been described, and cellular signalling pathways are known to be involved. There are currently two major cannabinoid receptors identified, whose roles in the activation of cell death remains controversial. Agonists to the type-2 receptor that do not have psychotropic effects have been used successfully in vitro, and we await the results of randomised trials using theses agents. The field of research into cannabinoids as anti-cancer agents is in its infancy, and more basic research is required before a good clinical agent can be realised. This article reviews the data currently available on this exciting group of potential anti-neoplastic agent.
Keywords: CB1-receptor, phosphodiesterases, neuromodulation, cyclo-oxygenase 2, signal transduction pathways
Letters in Drug Design & Discovery
Title: Cannabinoids: Do they have a Role in Cancer Therapy?
Volume: 3 Issue: 2
Author(s): W. M. Liu and Thomas B. Powles
Affiliation:
Keywords: CB1-receptor, phosphodiesterases, neuromodulation, cyclo-oxygenase 2, signal transduction pathways
Abstract: Cannabinoids, the active components of the cannabis plant, have merit as an anti-emetic and appetite stimulant in people with cancer. Recently, interest in cannabinoids has increased since reports that cannabinoids have anti-tumour activity. Although the mechanisms underlying these effects have yet to be fully elucidated, a broad spectrum of effects have been described, and cellular signalling pathways are known to be involved. There are currently two major cannabinoid receptors identified, whose roles in the activation of cell death remains controversial. Agonists to the type-2 receptor that do not have psychotropic effects have been used successfully in vitro, and we await the results of randomised trials using theses agents. The field of research into cannabinoids as anti-cancer agents is in its infancy, and more basic research is required before a good clinical agent can be realised. This article reviews the data currently available on this exciting group of potential anti-neoplastic agent.
Export Options
About this article
Cite this article as:
Liu M. W. and Powles B. Thomas, Cannabinoids: Do they have a Role in Cancer Therapy?, Letters in Drug Design & Discovery 2006; 3 (2) . https://dx.doi.org/10.2174/157018006775789676
DOI https://dx.doi.org/10.2174/157018006775789676 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Mass Spectrometry Characterization of Plant Phosphoproteins
Current Protein & Peptide Science Acid Sensing Ion Channels and Acid Nociception
Current Pharmaceutical Design Chemical Modifications of Ketoprofen (NSAID) in Search of Better Lead Compounds: A Review of Literature From 2004-2016
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tetrazoles: Synthesis and Biological Activity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fatty Acid-Binding Proteins at a Glance
Protein & Peptide Letters Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis
Current Cancer Drug Targets LPA and its Analogs-Attractive Tools for Elucidation of LPA Biology and Drug Development
Current Medicinal Chemistry Current Scenario in Structure and Ligand-Based Drug Design on Anti-colon Cancer Drugs
Current Pharmaceutical Design Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
Current Pharmaceutical Design Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma
Current Medicinal Chemistry Indole Curcumin Reverses Multidrug Resistance by Reducing the Expression of ABCB1 and COX2 in Induced Multidrug Resistant Human Lung Cancer Cells
Letters in Drug Design & Discovery Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Current Medicinal Chemistry Inhibition of Receptor Tyrosine Kinases in Combination with Chemotherapy for the Treatment of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Nanotechnology in Ophthalmic Drug Delivery: A Survey of Recent Developments and Patenting Activity
Recent Patents on Nanomedicine Patent Selections
Recent Patents on DNA & Gene Sequences Deubiquitinating Enzymes: Their Functions and Substrate Specificity
Current Protein & Peptide Science Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design NKT Cells: A Regulator in Both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents